Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia

WEE1 is a cell cycle and DNA damage response kinase that is emerging as a therapeutic target for cancer. AZD1775 is a small molecule inhibitor of WEE1, currently in early phase clinical trials as a single agent and in combination with more conventional anti-neoplastic agents. As resistance to kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, Tamara B., Uluisik, Rizvan C., van Linden, Annemie A., Jones, Kenneth L., Venkataraman, Sujatha, Vibhakar, Rajeev, Porter, Christopher C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066074/
https://www.ncbi.nlm.nih.gov/pubmed/32195191
http://dx.doi.org/10.3389/fonc.2020.00296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066074/
https://www.ncbi.nlm.nih.gov/pubmed/32195191
http://dx.doi.org/10.3389/fonc.2020.00296

Ejemplares similares